Gong Wen-Feng, Zhong Jian-Hong, Xiang Bang-DE, Li LE-Qun
Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China; Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning, Guangxi 530021, P.R. China.
Mol Clin Oncol. 2016 Jul;5(1):3-6. doi: 10.3892/mco.2016.871. Epub 2016 Apr 22.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-associated mortalities, and its prevalence is expected to increase in future decades. Hepatitis B virus (HBV) infection is the leading cause of HCC. Although hepatectomy is the preferred curative treatment for HCC, tumor recurrence is common, which is the most frequent cause of mortality in patients with HCC. HCC recurrence may originate from the primary tumor or be associated with remnant liver tissue, and include high viral load and hepatic inflammatory activity. Adjuvant transarterial chemoembolization and postoperative nucleos(t)ide analogs therapy are the two corresponding therapies. Following systematic searching of the PubMed database, the indications for adjuvant transarterial chemoembolization and nucleos(t)ide analog therapies for HBV-related HCC after hepatectomy were acquired. Additionally, the feasibility of combining these two therapies were also reviewed.
肝细胞癌（HCC）是癌症相关死亡的第三大主要原因，预计在未来几十年其患病率还会上升。乙型肝炎病毒（HBV）感染是HCC的主要病因。尽管肝切除术是HCC首选的根治性治疗方法，但肿瘤复发很常见，这是HCC患者最常见的死亡原因。HCC复发可能源于原发肿瘤或与残余肝组织有关，包括高病毒载量和肝脏炎症活动。辅助性经动脉化疗栓塞术和术后核苷（酸）类似物治疗是两种相应的治疗方法。在对PubMed数据库进行系统检索后，获得了肝切除术后辅助性经动脉化疗栓塞术和核苷（酸）类似物治疗HBV相关HCC的适应证。此外，还对这两种治疗方法联合应用的可行性进行了综述。
